Abstract
P53 is an important transcriptional factor that plays a pivotal role in different biological process (cell cycle, apoptosis, DNA repair, angiogenesis and cellular metabolism). While p53 binds to the promoter and increases the gene expression of Mdm2, MDM2 protein directly binds to p53 and inhibits its activity. Therefore, inhibitor of p53 and MDM2 has been considered as a potential cancer therapeutic agent due to the critical inhibitory role of MDM2 on p53. Small-molecule inhibitor of p53-MDM2 has been designed to serve as an effective way to treat cancer. Several compounds have moved into different phase of clinical trials based on major advances in the development of small-molecule inhibitors in recent years. Since there are few reviews covering the structure- activity relationship analysis of recent p53-MDM2 inhibitors reported from 2011 to the present time, in this review, attentions are focused on the development of p53-MDM2 inhibitors published from 2011 to the present time.
Keywords: Anticancer drug candidates, Crystal structures, p53-MDM2 inhibitors, Protein-protein interaction, Structure activity relationship analysis, Structure-based drug design, Xenograft model.
Current Medicinal Chemistry
Title:Recent Advances of p53-MDM2 Small Molecule Inhibitors (2011-Present)
Volume: 22 Issue: 5
Author(s): Peng-Cheng Lv, Juan Sun and Hai-Liang Zhu
Affiliation:
Keywords: Anticancer drug candidates, Crystal structures, p53-MDM2 inhibitors, Protein-protein interaction, Structure activity relationship analysis, Structure-based drug design, Xenograft model.
Abstract: P53 is an important transcriptional factor that plays a pivotal role in different biological process (cell cycle, apoptosis, DNA repair, angiogenesis and cellular metabolism). While p53 binds to the promoter and increases the gene expression of Mdm2, MDM2 protein directly binds to p53 and inhibits its activity. Therefore, inhibitor of p53 and MDM2 has been considered as a potential cancer therapeutic agent due to the critical inhibitory role of MDM2 on p53. Small-molecule inhibitor of p53-MDM2 has been designed to serve as an effective way to treat cancer. Several compounds have moved into different phase of clinical trials based on major advances in the development of small-molecule inhibitors in recent years. Since there are few reviews covering the structure- activity relationship analysis of recent p53-MDM2 inhibitors reported from 2011 to the present time, in this review, attentions are focused on the development of p53-MDM2 inhibitors published from 2011 to the present time.
Export Options
About this article
Cite this article as:
Lv Peng-Cheng, Sun Juan and Zhu Hai-Liang, Recent Advances of p53-MDM2 Small Molecule Inhibitors (2011-Present), Current Medicinal Chemistry 2015; 22 (5) . https://dx.doi.org/10.2174/0929867322666141128162557
DOI https://dx.doi.org/10.2174/0929867322666141128162557 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biosafety of Onco-Retroviral Vectors
Current Gene Therapy Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Selenosemicarbazone Metal Complexes as Potential Metal-based Drugs
Current Medicinal Chemistry Reactivation of p53 by Inhibiting Mdm2 E3 Ligase: A Novel Antitumor Approach
Current Cancer Drug Targets Efficacy of Pegylated Lyposomal Anthracyclines and of Intra-Arterial Carboplatin and Doxorubicin Combined with Local Hyperthermia in a Case of Malignant Endovascular Papillary Angioendothelioma
Current Drug Delivery Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story
Current Pharmaceutical Design Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene
Current Drug Targets Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Current Medicinal Chemistry Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Important Classes of Bioactive Alkaloids from Marine Ascidians: Structures, Isolation and Bioactivity
Current Topics in Medicinal Chemistry Small Molecule Inhibitors of p53/MDM2 Interaction
Current Topics in Medicinal Chemistry Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents